Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 32, Issue 3-4, 2005, Pages 419-439

  Shi, Jun ^a,c   Kovacs, Steven J ^a   Wang, Yaning ^a   Ludden, Thomas M ^b   Bhargava, Vijay O ^a  

^a SANOFI   (France)

^b ICON Development Solutions   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Juvenile rheumatoid arthritis; Leflunomide; NONMEM; Pediatrics; Population pharmacokinetics

Indexed keywords

4 TRIFLUOROMETHYLANILINE; DRUG METABOLITE; LEFLUNOMIDE; M 1; METHOTREXATE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BODY WEIGHT; CHILD; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; EVALUATION; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MONTE CARLO METHOD; PEDIATRICS; PREDICTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISOXAZOLES; MALE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; RANDOMIZED CONTROLLED TRIALS;

EID: 28444462494     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-005-0049-8     Document Type: Article

References (26)

1. Prescribing Information for Arava Tablets (Leflunomide). March 2004
2. V. Strand S. Cohen M. Schiff A. Weaver R. Fleischmann G. Cannon 1999 Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate Arch Intern. Med. 159 2542 2550
3. P. Tugwell G. Wells V. Strand A. Maetzel C. Bombardier B. Crawford 2000 Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial Arthritis. Rheum. 43 506 514
4. J.R. Kalden D.L. Scott J.S. Smolen M. Schattenkirchner B Rozman B.D. Williams 2001 Improved functional ability in patients with rheumatoid arthritis: long-term treatment with leflunomide versus sulfasalazine J. Rheumatol. 28 1983 1991
5. J.S. Smolen J.R. Kalden D.L. Scott B. Rozman T.K. Kvien A. Larsen 1999 The European Leflunomide Study Group. Efficacy and safety of leflunomide compared with sulfasalazine in active rheumatoid arthritis: a double-blind, randomized, multicenter trial Lancet 353 259 266
6. A. Larsen T.K. Kvien M. Schattenkirchner R. Rau D.L. Scott J.S Smolen 2001 Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine Scand. J. Rheumatol. 30 135 142
7. D.L. Scott J.S. Smolen J.R. Kalden L.B.A. van de Putte A. Larsen T.K. Kvien 2001 Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine Ann. Rheum. Dis. 60 913 923
8. J.T. Sharp V. Strand H. Leung F. Hurley I. Loew-Fridrich 2000 Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis Leflunomide rheumatoid Arthritis Investigators Group Arthritis Rheum. 43 495 505
9. J.R. Kalden M. Schattenkirchner H. Sorensen P. Emery C. Deighton B. Rozman 2003 The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow-up study Arthritis. Rheum. 8 1513 1520
10. B. Rozman 2002 Clinical pharmacokinetics of leflunomide Clin Pharmacokinet. 41 421 430
11. M.E. Weinblatt J.M. Kremer J.S. Coblyn A.L. Maier S.M. Helfgott M. Morrell 1999 Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis Arthritis. Rheum. 42 1322 1328
12. J. Li H.W. Yao Y. Jin Y.F. Zhang C.Y. Li Y.H. Li S.Y. Xu 2002 Pharmacokinetics of leflunomide in Chinese healthy volunteers Acta Pharmacol. Sin. 23 551 555
13. J.P. Davis G.A. Cain W.J. Pitts R.L. Magolda R.A. Copeland 1996 The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase Biochemistry 35 1270 1273
14. L.D. Fairbanks M. Bofill K. Ruckemann H.A. Simmonds 1995 Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans: disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors J. Biol Chem. 270 29682 29689
15. R.R. Bartlett H. Anagnostopulos T. Zielinski T. Mattar R Schleyerbach 1993 Effects of leflunomide on the immune responses and models of inflammation Springer. Semin. Immunopathol. 14 381 394
16. J. T. Cassidy. Juvenile rheumatoid arthritis. In Kelley W.N., Harris E.D., Ruddy S., and C. B. Sledge (eds.) Textbook of Rheumatology. Fifth Edition. WB Saunders, 1996, 1207-1254
17. B. Nepom 1991 The immunogenetics of juvenile rheumatoid arthritis Rheum. Dis. No. Amer. 17 825 842
18. W. Weber and L. Harnisch: Use of a population approach to the development of leflunomide: A new disease-modifying drug in the treatment of rheumatoid arthritis. Hoechst Marion Roussel. COST B1 medicine, Geneva 1997, 239-244
19. E.H. Giannini N. Ruperto A. Ravelli D.J. Lovell D.T. Felson A. Martini 1997 Preliminary definition of improvement in juvenile arthritis Arth. Rheum. 40 1202 1209
20. Beal S.L., Sheiner L.B. (Eds). NONMEM Users Guides. GloboMax, a Division of ICON plc, Hanover, MD, 1989-1998
21. E.I. Ette T.M. Ludden 1995 Population pharmacokinetic modeling: the importance of informative graphics Pharma. Res. 12 1845 1855
22. A. Gelman J.B. Carlin H.S. Stern D.B. Rubin 1995 Bayesian Data Analysis Chapman & Hall London
23. A.S. Kalgutkar H.T. Nguyen A.D. Vaz A. Doan D.K. Dalvie D.G [tmp] McLeod J.C. Murray 2003 In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes Drug Metab Dispos. 31 1240 1250
24. G. Geborek M. Crnkic I.M. Peterson T. Saxne 2002 Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up program in southern Sweden Ann. Rheum. Dis. 61 793 798
25. C. Siva S.A. Eisen R. Shepherd F. Cunningham M.A. Fang W. Finch 2003 Leflunomide use during the first 33 months after Food and Drug Administration Approval: Experience with a national cohort of 3,325 patients Arthritis Rheumatism (Arthritis Care & Research) 49 745 751
26. Silverman E., Spiegel L., and Jung L.K., et al. Efficacy and safety of leflunomide (LEF) versus methotrexate (MTX) in the treatment of pediatric patients with juvenile rheumatoid arthritis (JRA) Late-Breaking Abstracts. Program and abstracts of the American College of Rheumatology 67th Annual Scientific Meeting, October 23-28, 2003; Orlando, Florida. Abstract LB2